Developing a kit to diagnose and predict outcomes of brain injuries.
Official title: Cilia Biomarker Kit Development for Brain Injury Diagnosis and Prognosis.
Funded at Cian, INC. · NIH-11006498 · Data updated 2026-11-12
This study is working on a new blood test that looks for certain proteins to help doctors better understand how serious a traumatic brain injury is and how well someone might recover, making it easier to provide the best care for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cian, INC. NIH-funded |
| Lab location | 1 site (Pewaukee, United States) |
| Project start | August 29, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $369,886 |
| NIH project number | 1R41NS139906-01A1 |
| Project ID | NIH-11006498 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults over 21 years old who have experienced a traumatic brain injury.
✕Less likely to help
Patients with brain injuries that are not classified as traumatic or those under 21 years old may not benefit from this research.
What this research studies
This research focuses on improving the diagnosis and prognosis of traumatic brain injuries (TBI) by developing a biomarker kit that utilizes specific proteins found in blood. The approach involves analyzing ciliary proteins, which are sensitive to blood flow changes, alongside established neuronal and glial markers to enhance outcome predictions for TBI patients. By identifying these biomarkers, the research aims to provide more accurate assessments of brain injury severity and recovery potential, ultimately improving patient care.
Why it matters
Potential benefit: If successful, this research could lead to more accurate diagnoses and better prognostic tools for patients with traumatic brain injuries.
How similar studies have gone: Previous research has shown promise in using biomarkers for TBI diagnosis, but the specific approach of combining ciliary proteins with existing markers is relatively novel.
Where this research is happening
-
Cian, INC.
Pewaukee, United States Active
Researchers
- Principal investigator: Ramchandran, Ramani — Cian, INC.
- Study coordinator: Ramchandran, Ramani
Related research
Other NIH-funded projects on the same topics.
-
Cilia-based blood test to detect and predict recovery after brain injury
A blood test that combines cilia-related vascular proteins with known brain markers to help adults with traumatic brain injury detect injury and predict recovery.
-
Waixenicin A-based therapy for newborn brain injury
A new drug-target approach aims to protect babies’ brains after oxygen deprivation at birth.
-
AI-enhanced virtual reality tool to support remote emergency brain surgery training in Tanzania
A new AI-powered virtual reality tool helps non-experts in low-resource areas get real-time remote guidance for emergency traumatic brain injury surgery.
-
Modulating a brain lipid to reduce injury after newborn brain injury
Aims to test a treatment that changes a brain lipid to lessen damage after a baby’s brain has been deprived of oxygen.
-
Colorectal cancer prognosis through a broad, collaborative study
A large, multi-center study follows people newly diagnosed with colorectal cancer to find biomarkers and patterns that predict outcomes and guide future care.
-
AI-powered digital pathology to tailor cancer treatment decisions
A team at Emory is building an AI-powered platform that analyzes cancer slides to help doctors choose the right therapies and avoid unnecessary chemotherapy or radiation for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.